about
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations.Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'?An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives.Tubulin inhibitors in non-small cell lung cancer: looking back and forward.Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report.Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.The development of PARP as a successful target for cancer therapy.Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?Progress in the Management of Advanced Thoracic Malignancies in 2017.Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.Do immune checkpoint inhibitors need new studies methodology?Hyperprogressive disease: recognizing a novel pattern to improve patient managementModulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitorsEfficacy and safety of immunotherapy in elderly patients with non-small cell lung cancerAnti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-LetterPredictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancerImpact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung CancerCirculating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patientsAfatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre studyHyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent ChemotherapyOutcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint InhibitorsPseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapyThe Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural MesotheliomaHyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer-In ReplySurvival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitorsChoosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out
P50
Q37209474-86FD5823-4B2F-4F87-8B88-B71810C1AC91Q38266331-6936751E-C56D-4EB5-8008-5EEB582E86E0Q38525073-1B9703AC-982C-4D24-8A14-BBF16784FF4DQ38550459-7AC8389F-6BA6-43D2-ABD5-7C4C01C51048Q38742506-28F232E5-23E4-4037-A396-096E1DF00AEFQ38776942-603641D0-E4D8-45C5-966A-8E5AC84D0FDBQ38816700-50510C00-1AC8-41ED-A923-8A18E87EE12DQ41981114-4B13C625-DA17-4061-8283-44F94CD600D4Q47278103-9E66AE5F-2D05-4225-84BB-BA42E38F7D55Q47613099-5E76FCDF-B221-4501-9A09-775ED6CF35A8Q47956599-B3827DB7-0376-4ACF-8632-2209FE04B870Q50054820-BEB84EB2-75A1-4108-BF67-3977F6701AE1Q50074196-97FAB9D7-DC78-4C4A-AED0-F87730095E16Q55375458-ABF7FDF4-456C-4210-A824-118946F434D0Q58561264-887B80F3-397A-4854-8772-F4F3B7911066Q64094662-17ACCFFC-4274-44BC-8C48-F720512EEBC7Q90130541-FD987A5A-481D-4662-B999-E1A31E2976A0Q90258601-5E742C32-F759-46C9-A39C-661674F30E84Q90354457-3E28934C-1AB2-44CC-B04C-1C739768CC9AQ91038984-8E31079D-46B8-416B-B3C1-1D91ADBBD155Q91069251-5D09FFB3-7AA3-4846-9FB1-406AD4693202Q91238323-A78BA555-BCFA-499D-9E64-6247F43BC5C5Q91332386-3A52649A-C0D3-45AD-BF60-218E7C7FA964Q91704817-19D58C3C-922F-46F2-8C19-19324938E2B1Q91721663-56A2B43C-C054-4EB3-B945-B57BE2F95E38Q92142291-24198A35-F466-4FB9-BDEE-BB86196288A0Q92385844-73FA74C3-9A3D-47F8-8902-F6D983FBE556Q92524740-3301DB5F-0966-42A8-8ECE-80C0B458E2D3Q92774133-1180F72A-209C-4EBF-A027-C100DE12A34CQ92897874-D789A7E5-3941-4B35-999F-81625B9DDC72
P50
description
researcher, ORCID id # 0000-0001-6443-5642
@en
wetenschapper
@nl
name
Roberto Ferrara
@ast
Roberto Ferrara
@en
Roberto Ferrara
@es
Roberto Ferrara
@nl
type
label
Roberto Ferrara
@ast
Roberto Ferrara
@en
Roberto Ferrara
@es
Roberto Ferrara
@nl
prefLabel
Roberto Ferrara
@ast
Roberto Ferrara
@en
Roberto Ferrara
@es
Roberto Ferrara
@nl
P106
P1153
56680868500
P21
P31
P496
0000-0001-6443-5642